2 news items
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
CNTB
7 May 24
. Session: Poster Discussion D21: Terminator: Control of Airway Inflammation and Immune Response in Asthma Session Date and Time
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
CNTB
16 Apr 24
the China pivotal trial in patients with moderate-to-severe AD in November 2023. Clinical response (IGA0/1 and EASI-75) achieved at Week 16 (Stage 1
- Prev
- 1
- Next